AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02518217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Apps
Description: Provision of commercially available smartphone applications for healthy eating, physical activity, and weight loss.
Study NCT02518217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ShapeUp Empower
Description: Online intervention with training in behavioral strategies for healthy eating, physical activity, and weight loss. Includes periodic feedback on weight loss progress and engagement with the intervention platform.
Study NCT02518217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives for Engagement
Description: Financial incentives for completing tasks such as viewing instructional information and reporting self-monitored body weights via the study website.
Study NCT05751876 — intervention group
Intervention type: DRUG
Intervention: Dienogest
Description: Dienogest 2mg was prescribed once per day orally
Study NCT04044560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blinatumomab
Description: Continuous intravenous infusion
Study NCT04572204 — intervention group
Intervention type: OTHER
Intervention: Surgical
Description: Minimal: Such as PCN insertion Endosopic: Such as DJ insertion Surgical: Repair, Partial or total nephrectomy Angioembolization
Study NCT01429831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.
Study NCT05181800 — intervention group
Intervention type: OTHER
Intervention: Degarelix Cohort
Description: Non-interventional
Study NCT00224484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK208141
Description: 3 intramuscular doses
Study NCT00224484 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix (investigational formulation)
Description: 3 intramuscular doses
Study NCT03935347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT03935347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03935347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes LN-145
Description: Given IV
Study NCT03935347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study NCT02304185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140, 50 mcg
Description: Glycoprotein 140 (gp140) vaccine containing 50 microgram (mcg) total protein will be administered intramuscularly on Day 1 and Day 29.
Study NCT02304185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140, 50 mcg + Adjuvant
Description: The gp140 vaccine containing 50 mcg total protein mixed with 0.425 milligram (mg) aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
Study NCT02304185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140, 250 mcg
Description: The gp140 vaccine containing 250 mcg total protein will be administered intramuscularly on Day 1 and Day 29.
Study NCT02304185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140, 250 mcg + Adjuvant
Description: The gp140 vaccine containing 250 mcg total protein mixed with 0.425 mg aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
Study NCT02304185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to gp 140 vaccine drug product will be administered intramuscularly on Day 1 and Day 29.
Study NCT02290912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education program
Description: The intervention is a health education program including: informational website, experiential classes, custom smart phone or smart table application, wearable activity monitor, and informal coaching by student researchers to provide moral support for lifestyle behavioral change goals. Participants are not placed on any specific behavioral regimen but instead are encouraged to adopt healthier lifestyle behaviors per the evidence-based health education program, and to attend the experiential classes cafeteria style (i.e. based on their individual preferences).
Study NCT03725592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Participant households receive a point of use arsenic removal device and a replacement filter. Households are also provided with an instruction manual on how to use the device.
Study NCT03725592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Participant households receive a point of use arsenic removal device and a replacement filter. Households are also provided with an instruction manual on how to use the device.
Study NCT03725592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Education
Description: Participant households receive up to five additional in-person visits and phone calls to provide support regarding the health implications of arsenic and the proper use and maintenance of the arsenic removal device.
Study NCT02082977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2816126
Description: GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.
Study NCT01215331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulins most commonly used during pregnancy by our group are rapid acting insulins and long acting human insulins (long acting analogs are not authorized in pregnancy). An ultra-fast acting insulin will be started before a meal (1, 2 or 3 meals) at 4-6 IU (according to the weight) if the glycemic value 2 hours after this meal is ≥ 6.7 mmol/L in 50% of cases. It will be increased by 2 units every 2 days until obtaining the aimed objectives. Long acting insulin will be started at 4-6 units at bedtime if the glycemic value before breakfast is ≥ 5.3 mmol/L in 50% of cases, and it will be increased by 2 units every 2 days until reaching the objective. A combination of both insulins could be necessary (maximum of 4 injections per day).
Study NCT01215331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, glyburide and insulin
Description: Metformin (tablets of 500 mg) will be started at 250 mg/day x 1 day, and increased thereafter by 250 mg per day every 3 days until obtaining an adequate glycemic control. If metformin does not prove its effect at a dose of 750 mg, or if the side effects (mainly gastric) command to slow down or not to increase the posology, glyburide will be added.~Glyburide (tablets of 5 mg) will be started at a dose of 2.5 mg and will be increased by 2.5 mg every 3 days until obtaining an adequate glycemic control. The maximal dose in the study will bw 10 mg. It corresponds to the half of the maximal dose recommended in Canada.~Treatment failure is defined as glycemia above the Canadian Diabetes Association therapeutic objectives in spite of maximal doses or whether the doses can not be increased because of side effects. Insulin will be added to oral hypoglycemic agents.
Study NCT00224484 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 intramuscular doses
Study NCT03497819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CARTmeso CART19
Description: Autologous chimeric antigen receptor T cells with murine scFv, 41BB co-stimulatory domain and CD3ζ signaling domain targeting mesothelin or CD19
Study NCT01839695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Mona LSA Stent Graft System
Description: All subjects will be implanted with this device
Study NCT03176524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone® glucagon formulation 1
Description: Injection of BioChaperone® glucagon formulation 1 at Day 1: 50 µg and at Day 2: 1 mg
Study NCT03176524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone® glucagon formulation 2
Description: Injection of BioChaperone® glucagon formulation 2 at Day 1: 50 µg and at Day 2: 1 mg
Study NCT03176524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GlucaGen® HypoKit®
Description: Injection of GlucaGen® HypoKit® at Day 1: 50 µg and at Day 2: 1 mg
Study NCT01085448 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Core Stabilization
Description: The 8-week program emphasizes use of specific local stabilizing muscles (transverse abdominis\[TrA\], lumbar multifidus\[LM\]) to restore active control to the trunk. Emphasis is on training isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: maintenance the co-contraction while performing movements of the trunk and the upper and lower extremities. Trunk conditioning is also emphasized. Feedback is gradually reduced.~Stage 3: maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning.
Study NCT04601402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN-001
Description: The capsules taken by mouth once a daily. Each capsule will contain ≥ 1x10\^11 colony-forming units (CFU)
Study NCT04601402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 800 mg given by intravenous (IV) infusion once every 2 weeks
Study NCT02514525 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CryoBalloon Ablation System
Description: CryoBalloon Ablation System, a balloon-based cryotherapy device, provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.
Study NCT02171065 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Study NCT02171065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABSORB BVS
Study NCT01435278 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glucosanol
Description: 2 tablets taken 3 times a day.
Study NCT04512417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+Radiotherapy
Description: The combined treatment group received radiotherapy for recurring or metastatic lesions: at least one or more lesions were irradiated, stereotactic body radiotherapy (SBRT, 8Gy/time, 3-5 times) or conventional radiotherapy (parts not suitable for SBRT, total Dose 30Gy or more); start immunotherapy within 8 weeks after radiotherapy.Until PD or toxicity is intolerable or up to 24 months.
Study NCT04512417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab,200mg,Q3W,Until PD or toxicity is intolerable or up to 24 months.
Study NCT02692222 — intervention group
Intervention type: OTHER
Intervention: Calculation of PPV and CO with two methods
Study NCT02837289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Therapy taping
Description: Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
Study NCT02837289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo taping
Description: Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
Study NCT02454725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network
Description: Leaders of social networks will undergo small group training to develop skills to convey information effectively and deliver messages endorsing regular HIV testing to members of their social networks.
Study NCT02454725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: All participants will receive HIV counseling and rapid testing following the Wisconsin Department of Health guidelines. Sexually active men who receive a negative test result will be told that they should be HIV-tested every three to six months, unless they have a monogamous HIV negative partner
Study NCT02454725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparison
Description: All participants will receive HIV counseling and rapid testing following the Wisconsin Department of Health guidelines. Sexually active men who receive a negative test result will be told that they should be HIV-tested every three to six months, unless they have a monogamous HIV negative partner
Study NCT01542320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Description: 1 x 10e8 colony forming units in 5 drops (0.17ml)daily from study enrollment to study conclusion. Duration based on rotavirus vaccine administration.
Study NCT01542320 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution without active Lactobacillus reuteri
Study NCT03854201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Exercise Counseling (PEC)
Description: At the first counseling appointment, PEC-participants answer the physical activity (PA) questionnaire, perform fitness tests and discuss with their exercise instructor. The target is a personalized short-term PA plan including where and when the PA/exercise takes place and what is the mode. Participants may choose instructed group-exercise sessions provided by the municipal sports/leisure sector or exercising alone as preferred. The exercise instructors utilize the fitness test results and feedback data of the research accelerometers by the UKK Institute to guide the participants. The PEC includes 2 more face-to-face sessions and 4-6 phone calls by the instructors aimed at checking the realization of exercise plans and discussing the outcomes provided by the interactive accelerometer.
Study NCT01564914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
Study NCT01564914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV
Study NCT02715180 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: low dose chest computed tomography
Description: All participants were evaluated 2 scout films during LDCT screenings. The first scout film was obtained while a participant was holding a comfortable expiration with the arms at down position, and the second scout film was obtained while a full inspiration with the arms at raised position. The axial images of LDCT were taken during participants' full inspiration. The radio-opaque marker was attached to the participants' skin where the lowest part of sternum was palpable, because the sternum moves according to the position of arms and respiration.
Study NCT04045275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm
Description: Calm provides daily, 10-minute, guided meditations grounded in mindfulness-based stress reduction (MBSR) and Vipassana meditation. Calm also offers Sleep Stories, developed using techniques from Cognitive Behavioral Therapy and Relaxation Technique. Clam also includes behavioral components to reinforce sustained practice.
Study NCT01446107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placement of fissure sealant
Description: placement of resin-based fissure sealant at baseline without replacement
Study NCT01446107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluoride varnish
Description: topical applications of a 5% sodium fluoride (NaF) varnish onto tooth surface every 6 months
Study NCT01446107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: silver fluoride
Description: topical applications of a 38% silver diamine fluoride (SDF) solution onto tooth surface every year
Study NCT01446107 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: application of water onto tooth surface every year
Study NCT03589833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tripterygium Wilfordii
Description: Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks.
Study NCT03589833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium Wilfordii
Description: Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks.
Study NCT03085368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib/herceptin
Description: Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer
Study NCT03085368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib/herceptin
Description: Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer
Study NCT03589833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.
Study NCT03589833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.
Study NCT03589833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yisaipu
Description: Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.
Study NCT01863186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine HCl
Description: Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.
Study NCT01863186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.
Study NCT01863186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.
Study NCT01863186 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Open Label Lofexidine HCL
Description: Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.
Study NCT04193319 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluzoparib
Description: PARP inhibitor
Study NCT04193319 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole
Description: inhibitor
Study NCT00781430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib (HKI-272)
Description: Neratinib 40-mg oral tablets. SINGLE DOSE of 120-mg (3 x 40-mg tablets)
Study NCT00982631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus/PLD
Description: This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
Study NCT03087786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Bitartrate Lozenge 4mg
Description: Test Product
Study NCT03087786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Polacrilex 4Mg Lozenge
Description: Active Comparator
Study NCT01332721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105 and Bevacizumab
Description: Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
Study NCT00745134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT00745134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO
Study NCT00745134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Given PO
Study NCT00745134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00745134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies